Truist Securities Upgrades Mersana Therapeutics to Buy, Maintains Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene upgraded Mersana Therapeutics (MRSN) from Hold to Buy while maintaining the price target at $9.
February 29, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mersana Therapeutics was upgraded by Truist Securities from Hold to Buy, with a maintained price target of $9.
Analyst upgrades typically lead to positive short-term price movement as they reflect a positive change in the analyst's view of the company's future prospects. Maintaining the price target suggests confidence in the company's valuation at that level.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100